Search results for Pro

Anti-Human CD195/CCR5 Antibody (PRO-140) (HW412107), abinScience, HW412107

N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody, Abbexa, abx170718

Human N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody is a Mouse monoclonal against N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP).

N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP) Antibody, Abbexa, abx170721

Human N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP) Antibody is a Mouse monoclonal against N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP).

Apitegromab Biosimilar – Anti-pro-GDF-8 mAb – Research Grade, ProteoGenix, PX-TA1810

Description of Apitegromab Biosimilar - Anti-pro-GDF-8 mAb - Research Grade Introduction to Apitegromab Biosimilar – Anti-pro-GDF-8 mAb – Research Grade Apitegromab Biosimilar, also known as Anti-pro-GDF-8 monoclonal antibody (mAb), is a research grade therapeutic antibody that is designed to target and inhibit the activity of growth differentiation factor 8 (GDF-8). GDF-8 is a protein that belongs to the transforming growth factor beta (TGF-β) superfamily and is involved in regulating muscle growth and development. Structure of Apitegromab Biosimilar Apitegromab Biosimilar is a fully humanized monoclonal antibody that is produced using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the specific target, GDF-8, while the constant regions provide stability and effector functions. The structure of Apitegromab Biosimilar is similar to that of the endogenous human antibodies, which reduces the risk of immunogenicity and increases its efficacy. The antibody has a molecular weight of approximately 150 kDa and a half-life of 21 days, making it suitable for therapeutic use. Mechanism of Action of Apitegromab Biosimilar Apitegromab Biosimilar works by binding to GDF-8 and preventing its interaction with its receptor, activin type II receptor (ActRII). This binding inhibits the downstream signaling pathways, such as Smad2/3, which are responsible for regulating muscle growth and differentiation. By blocking the activity of GDF-8, Apitegromab Biosimilar promotes muscle growth and regeneration. Moreover, Apitegromab Biosimilar also has an Fc region that can interact with immune cells, such as natural killer (NK) cells and macrophages, leading to the destruction of GDF-8-expressing cells. This effector function of the antibody further enhances its therapeutic potential. Applications of Apitegromab Biosimilar Apitegromab Biosimilar has potential applications in the treatment of various muscle-wasting disorders, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and sarcopenia. These conditions are characterized by a loss of muscle mass and strength, and GDF-8 has been identified as a key factor in their pathogenesis. Preclinical studies have shown promising results for Apitegromab Biosimilar in animal models of DMD and BMD. It has been found to increase muscle mass and strength, improve muscle function, and reduce fibrosis. The antibody has also been shown to have a synergistic effect when used in combination with other therapies, such as corticosteroids, in DMD treatment. Furthermore, Apitegromab Biosimilar has potential applications in sports medicine, where it can be used to enhance muscle growth and improve performance. It can also be used in the treatment of age-related muscle loss, or sarcopenia, which is a common problem in the elderly population. Conclusion In summary, Apitegromab Biosimilar is a research grade therapeutic antibody that targets GDF-8 and promotes muscle growth and regeneration. Its humanized structure, specific mechanism of action, and potential applications make it a promising candidate for the treatment of muscle-wasting disorders. Further research and clinical trials are needed to fully explore the therapeutic potential of this antibody.

N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody, Abbexa, abx170716

Human N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody is a Mouse monoclonal against N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP).

N-terminal Pro-Brain Natriuretic Peptide (NT-ProBNP) Antibody, Abbexa, abx020818

NT-ProBNP Antibody is a Mouse monoclonal antibody against NT-ProBNP.

N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody, Abbexa, abx173853

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody is a Mouse Monoclonal antibody against N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP).

Human IL-1α Precursor (Pro-IL-1a) ELISA Kit, Abbkine, KTE61130

• Do not mix components from different kit lots or use reagents beyond the kit expiration date.• Allow all reagents to warm to room temperature for at least 30 minutes before opening.• Pre-rinse the pipet tip with reagent, use fresh pipet tips for each sample, standard and reagent to avoid contamination. • Unused wells must be kept desiccated at 4 °C in the sealed bag provided.• Mix Thoroughly is very important for the result. It is recommended using low frequency oscillator or slight hand shaking every 10 minutes.• It is recommended that all samples and standards be assayed in duplicate or triplicate.

N-Terminal Pro-Atrial Natriuretic Peptide (NT-ProANP) Antibody, Abbexa, abx131394

NT-ProANP Antibody is a Rabbit Polyclonal against NT-ProANP.

N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP) Antibody, Abbexa, abx217223

N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP) Antibody is a Rabbit Polyclonal antibody for the detection of NPPB. NPPB, also known as B-type natriuretic peptide (BNP), is a cardiac hormone that is secreted mainly in the ventricles in response to increased wall stress. The protein undergoes two cleavage events, one within the cell and a second after secretion into the blood. The protein's biological actions include natriuresis, diuresis, vasorelaxation, inhibition of renin and aldosterone secretion, and a key role in cardiovascular homeostasis. BNP is a marker of systolic and diastolic dysfunction and a strong predictor of mortality in heart failure patients.